Prophylactic effect of colchincine and amiodarone - Trial PACTR202101651961317
Access comprehensive clinical trial information for PACTR202101651961317 through Pure Global AI's free database. This Phase 2 trial is sponsored by Tanta university and is currently Completed. The study focuses on Cardiology.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Pan Africa Clinical Trials Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Tanta university
Mohamed Ali mahmoud Ahmed
Timeline & Enrollment
Phase 2
Dec 01, 2019
Feb 28, 2022
Summary
AF is one of the most common arrhythmic complication in patients undergoing coronary artery bypass grafting (CABG) as it incidence varies from 25.6% to 31% primarily within 2 to3days. .Amiodarone has been widely used for clinical purposes. Despite its antiarrhythmic characteristic, the use of this drug as a prophylactic agent against the occurrence of postoperative AF is uncommon and yet the use of amiodarone as prophylaxis in patients undergoing CABG is not routine. On the other hand, the role of amiodarone in reducing the post-CABG AF is controversial. Although preliminary data from using colchicine for prevention of the post pericardiotomy syndrome and postoperative atrial fibrillation (COPPS) trial for 1-month postoperative treatment with colchicine were promising. But there is a limitation of the COPPS trial was that colchicine was begun on postoperative day 3. Its beneficial effect may be further optimized when colchicine is started before surgery. So objective of this study is to investigate the effect of amiodarone and colchicine in reduction of post-CABG atrial fibrillation.
ICD-10 Classifications
Data Source
Pan Africa Clinical Trials Registry
PACTR202101651961317
Non-Device Trial